南方财经3月24日电,今日,阿斯利康宣布重度嗜酸粒细胞性哮喘(SEA)创新靶向生物制剂凡舒卓® (通用名:本瑞利珠单抗注射液)在中国正式商业上市,用于成人和12岁及以上青少年重度嗜酸粒细胞性哮喘的维持治疗。本瑞利珠单抗是精准靶向嗜酸性粒细胞(EOS)的抗IL-5R创新生物制剂。(21世纪经济报道)
(文章来源:南方财经网)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.